title: Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002.
abstract: Proportion cured is a potentially more informative cancer outcome measurement than 5-year survival. We present population-based estimates of cure for young patients diagnosed with acute lymphoblastic leukemia in Europe from 1982 to 2002. Thirty-five European cancer registries provided data. Survival was estimated by age, period of diagnosis and European region, and used as input for parametric cure models, which assume cured patients have the same mortality as the general population. For acute lymphoblastic leukemia diagnosed in 1-14 year olds in 2000-2002, over 77% were estimated cured. The proportion cured improved significantly over the study period: an impressive 26-58% in infants (up to 1 year), 70-90% in 1-4 year olds, 63-86% in 5-9 year olds, 52-77% in 10-14 year olds, and 44-50% in 15-24 year olds. Regional variations in proportion cured reduced over time for 1-14 year-olds, but persisted in infants and 15-24 year olds. Five-year survival was always slightly higher than proportion cured. Considerable proportions of young patients were estimated cured of acute lymphoblastic leukemia. Nevertheless, a small excess risk of death persisted beyond five years after diagnosis when patients remained at risk for late treatment effects, late relapses and second primaries.
authors: Evaluative Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. gemma.gatta@istitutotumori.mi.it
authors: Gemma
authors: G
authors: Gatta
authors: Silvia
authors: S
authors: Rossi
authors: Roberto
authors: R
authors: Foschi
authors: Annalisa
authors: A
authors: Trama
authors: Rafael
authors: R
authors: Marcos-Gragera
authors: Guido
authors: G
authors: Pastore
authors: Rafael
authors: R
authors: Peris-Bonet
authors: Charles
authors: C
authors: Stiller
authors: Riccardo
authors: R
authors: Capocaccia
mesh_terms: D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D005060:Europe / Q000453:epidemiology; D005260:Female; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology / Q000266:history / Q000401:mortality*; D012042:Registries; D055815:Young Adult
references: J Clin Oncol. 2012 May 10;30(14):1663-9
references: 22412151
references: J Clin Oncol. 2009 May 10;27(14):2328-38
references: 19332714
references: Curr Oncol Rep. 2011 Oct;13(5):371-8
references: 21744057
references: Clin Adv Hematol Oncol. 2006 Nov;4(11):804-5
references: 17143248
references: Eur J Cancer. 2006 Sep;42(13):2006-18
references: 16919767
references: Int J Cancer. 2007 Nov 15;121(10):2233-40
references: 17557301
references: J Clin Oncol. 2010 Mar 1;28(7):1224-31
references: 20124180
references: Eur J Cancer. 2009 Apr;45(6):909-30
references: 19128955
references: Biometrics. 1982 Dec;38(4):933-42
references: 7168796
references: Br J Cancer. 2008 Jul 8;99(1):219-23
references: 18594545
references: Eur J Cancer. 2009 Apr;45(6):992-1005
references: 19231160
references: Ann Oncol. 2007 Sep;18(9):1569-77
references: 17660497
references: Haematologica. 2008 Aug;93(8):1161-8
references: 18556413
references: JAMA. 2010 Jul 14;304(2):172-9
references: 20628130
references: Cancer. 2005 Apr 1;103(7):1457-67
references: 15712273
references: Eur J Cancer. 2006 Sep;42(13):2019-36
references: 16919768
references: Klin Padiatr. 2005 Nov-Dec;217(6):310-20
references: 16307416
references: IARC Sci Publ. 1994;(128):1-302
references: 7698823
references: Int J Cancer. 1998 Jul 29;77(3):322-9
references: 9663589
references: Lancet. 2007 Jul 21;370(9583):240-250
references: 17658395
references: Eur J Pediatr. 2004 Jun;163(6):313-9
references: 15346913
references: Pediatr Blood Cancer. 2008 May;50(5 Suppl):1101-4
references: 18360838